Anti-SARS-CoV-2 Biotherapeutics and Chemotherapeutics: An Insight into Product Specifications and Marketing Dynamics

Authors

  • Vijay Kotra
  • Dinakar Mallem
  • Anil Kumar Kanuri
  • Mahesh Reddy Burra
  • Shaik Nyamathullah
  • Looi Shu Ying
  • Khairul Anwar Husain
  • Ravi Varala
  • Madhadevi Sudhakar
  • Khang Wen Goh
  • Toong Hai Sam
  • Long Chiau Ming

DOI:

https://doi.org/10.36877/pmmb.a0000323

Abstract

Chemotherapeutics and biotherapeutics agents have been explored as a potential treatment for COVID-19. This study was aimed to elucidate latest update related to biotherapeutics and chemotherapeutics against COVID-19 and its variants as well as the product specifications and marketing dynamics of its pharmacotherapies. There are several chemotherapeutics that have been studied for the treatment of COVID-19, including Paxlovid (Nirmatrelvir & Ritonavir) fixed dose combination, nirmatrelvir and ritonavir fixed dose combination, Remdesivir (Vekulary/Covifor) fixed dose combination, chloroquine and hydroxychloroquine, molnupiravir, favipiravir, Infliximab (Remsima®) fixed dose combination tocilizumab (Actimera), casirivimab+imdevimab (Ronapreve) fixed dose combination, ivermectin, methylprednisole. These drugs have been repurposed for use in COVID-19 due to their antiviral properties and ability to reduce inflammation. The COVID-19 death cases have significantly reduced because of tested efficacy of advanced biotherapeutics and chemotherapeutics. As for marketing dynamics, the demand for chemotherapeutics for the treatment of COVID-19 has increased significantly since the outbreak of the pandemic. Hence, the prices of anti-viral and monoclonal antibodies in top COVID-19 affected countries is also presented here. Considering the molecular interactions, therapeutic activity, efficacy, and adverse effects, the USFDA and the WHO recommended the aforementioned drugs. The chances of approval seems favouring biotherapeutics as these have the best characteristics among the chemotherapeutics. Overall, this review contributes to the scientific understanding of the COVID-19. This can help to inform future research and development efforts and contribute to the overall advancement of knowledge in the field of medicine.

Downloads

Published

2022-12-30

How to Cite

Kotra, V., Mallem, D., Kanuri, A. K., Burra, M. R., Nyamathullah, S., Ying, L. S., Husain, K. A., Varala, R., Sudhakar, M., Goh, K. W., Sam, T. H., & Ming, L. C. (2022). Anti-SARS-CoV-2 Biotherapeutics and Chemotherapeutics: An Insight into Product Specifications and Marketing Dynamics. Progress In Microbes & Molecular Biology, 5(1). https://doi.org/10.36877/pmmb.a0000323

Issue

Vol. 5 No. 1 (2022)

Section

Review Articles

License

Copyright (c) 2022 Vijay Kotra, Dinakar Mallem, Anil Kumar Kanuri, Mahesh Reddy Burra, Shaik Nyamathullah, Looi Shu Ying, Khairul Anwar Husain, Ravi Varala, Madhadevi Sudhakar, Khang Wen Goh, Toong Hai Sam, Long Chiau Ming

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Author(s) shall retain the copyright of their work and grant the Journal/Publisher right for the first publication with the work simultaneously licensed under:

Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). This license allows for the copying, distribution and transmission of the work, provided the correct attribution of the original creator is stated. Adaptation and remixing are also permitted.

 

This broad license intends to facilitate free access to, as well as the unrestricted reuse of, original works of all types for non-commercial purposes.

The author(s) permits HH Publisher to publish this article that has not been submitted elsewhere.

Abstract viewed = 601 times
PDF downloaded = 444 times